Enabling Scientific Innovation
The global healthcare environment is changing at a rapid pace and in South Africa, and the African continent, we are sitting on a veritable non-communicable disease time bomb. Cardiovascular diseases, diabetes, obesity and smoking related illnesses, are becoming increasingly prevalent and the scourge of Africa, but the continent is ill equipped to fight these modern day illnesses; it does not have the empirical data to properly treat these potentially life-threatening diseases. From disease prevalence, to patient presentation and treatment patterns, there is a complete lack of epidemiological data.
Critically aware of the need for funding that will develop research capacity and contribute to academic advancement in South Africa, AstraZeneca Pharmaceuticals has set up a not for profit Fund for the disbursement of medical research funding for high level non-interventional studies that will generate significant data currently not available.
Non-Communicable Disease study applications ONLY will be considered
Applications closed on 21 April 2018. Successful applicants will be notified at the end of October 2018.
Research & Development
AstraZeneca has a world-class record of successful Research and Development (R&D) aimed at generating a flow of new prescription medicines.
The Research Fund Committee comprises a scientific review panel.
A total of 25 research grants have been conferred locally by the Fund since its inception. The 2018 grant shortlist will be announced in June 2018.